`JP02001261553A
`DOCUMENT-IOENTIFIER: JP ;2001.2615'5~ A-
`TITLE:
`ORAL PHARMACEUTICAL PREPARATION
`
`POBN-DATE:
`
`September 26, 2001
`
`INVENTOR-INFORMATION:
`
`COUNTRY
`NAME
`KOIDA, YOSHIYUKI N/A
`YAO, TAKASHI
`N/A
`MATSUBARA, KOJI N/A
`
`ASSIGNEE-INFORMATION:
`
`COUNTRY
`NAME
`TANABE SEIYAKU CO LTDN/A
`UBE IND LTD
`N/A
`
`APPL-NO:
`JP2000079499
`APPL-DATE: March 22, 2000
`
`INT-CL
`(IPC) :
`
`A61K009/20
`A61K047/34
`A61P037/08
`
`I A61K047/26
`I A61K009/30 I A61K031/4545
`I A61K047/38
`I A61P011/06 I A61P027/16 I
`I C07D401/12
`
`I
`
`ABSTRACT:
`
`PROBLEM TO BE SOLVED: To provide a bepotastine-including
`pharmaceutical preparation that includes bepotastine [(S)-4-[4-[4-
`chlorophenyl] (2-pyridyl)-methoxy]piperidino] butyric acid] of s(cid:173)
`configuration in high optical purity and has markedly improved
`storage stability because of no occurrence of racemization.
`
`SOLUTION: The objective oral solid pharmaceutical preparation is
`obtained by formulating an excipient selected from mannitol, sucrose,
`lactose and a mixture thereof and polyethylene glycol to bepotastine
`a pharmaceutically acceptable salt thereof.
`
`6/2112007, EAST Version: 2.0.3.0
`
`SENJU EXHIBIT 2010
`MYLAN v. SENJU
`IPR2016-00626
`
`Page 1 of 1